<DOC>
	<DOC>NCT00152035</DOC>
	<brief_summary>The purpose of this study is to assess the safety and effectiveness of SPD465 in the treatment of ADHD. The study will also look at how SPD465 affects sleep.</brief_summary>
	<brief_title>Safety of SPD465 in Treating Adults With ADHD.</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>Subject satisfied all entry criteria for the antecedent protocol (SPD465301 or SPD465303) and completed a minimum of 4 of the 7 weeks of doubleblind treatment without experiencing any clinically significant adverse events. Subject must be male or nonpregnant female who agrees to comply with using acceptable contraceptive methods. Subject was terminated from antecedent protocol (SPD465301 or SPD465303) for noncompliance and/or experienced a serious adverse event or adverse event resulting in termination from the protocol. Comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or severe Asix I disorders. History of seizure, tic disorder, or a current diagnosis and/or family history of Tourette's Disorder. Females who are pregnant of lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>